Cardiovascular risk profile and events before and after treatment with anti-VEGF drugs in the setting of a structured cardio-oncologic program

Eur J Prev Cardiol. 2021 Aug 9;28(9):e38-e40. doi: 10.1177/2047487320923056.
No abstract available

Publication types

  • Letter

MeSH terms

  • Angiogenesis Inhibitors / adverse effects
  • Cardiovascular Diseases* / diagnosis
  • Cardiovascular Diseases* / epidemiology
  • Cardiovascular Diseases* / prevention & control
  • Heart Disease Risk Factors
  • Humans
  • Risk Factors
  • Vascular Endothelial Growth Factor A

Substances

  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factor A